Related Experiment Videos
Combination chemotherapy with oral etoposide.
D H Johnson1, J D Hainsworth, K R Hande
1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN.
Seminars in Oncology
|December 1, 1992
Summary
Protracted etoposide administration, up to 21 days, shows promise for treating lung cancer. Combining oral etoposide with platinum agents like cisplatin or carboplatin is being investigated for improved efficacy in managing neoplasms.
Area of Science:
- Oncology
- Cancer Chemotherapy
Background:
- Chronic administration of etoposide is effective against various neoplasms.
- Traditional etoposide treatment duration is 3-5 days.
- Recent studies indicate 21-day etoposide administration has acceptable toxicity.
Purpose of the Study:
- To review the efficacy and toxicity of protracted etoposide administration.
- To evaluate combined oral etoposide with cisplatin or carboplatin in Phase II trials.
- To assess the management of small cell and non-small cell lung cancer with extended etoposide schedules.
Main Methods:
- Review of previous institutional work on protracted etoposide.
- Phase II clinical trials combining oral etoposide with cisplatin or carboplatin.
- Administration of etoposide orally for 21 consecutive days.
Main Results:
- Previous work confirmed etoposide's activity in lung cancer.
- Phase II trials combined oral etoposide with platinum agents.
- Results of these trials are under review for efficacy and toxicity.
Conclusions:
- Extended etoposide administration (up to 21 days) is feasible with acceptable toxicity.
- Combined oral etoposide and platinum agents are being investigated for selected malignancies.
- Further studies are warranted to determine the optimal protracted etoposide schedule for cancer management.